Antibody data
- Antibody Data
- Antigen structure
- References [63]
- Comments [0]
- Validations
- Western blot [1]
- Immunocytochemistry [3]
- Immunohistochemistry [1]
- Flow cytometry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MA1-12693 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- EGFR Monoclonal Antibody (H11)
- Antibody type
- Monoclonal
- Antigen
- Other
- Description
- MA1-12693 detects Epidermal Growth Factor Receptor in human samples. MA1-12693 has been successfully used in FACS, immunofluorescence, immunoprecipitation, Western blot, and immunohistochemistry (paraffin) procedures. Staining of formalin-fixed tissues requires digestion with protease xxv at 1 mg/mL in PBS for 5 minutes at 37ºC. Positive controls include A431 cells or placenta or squamous cell carcinoma. Suitable for Western blotting of extracellular domain of EGFR. The MA1-12693 immunogen is HC2 20 d2 cells.
- Reactivity
- Human, Mouse
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- H11
- Vial size
- 100 µg
- Concentration
- 1 mg/mL
- Storage
- -20°C
Submitted references A Patient-Derived Glioblastoma Organoid Model and Biobank Recapitulates Inter- and Intra-tumoral Heterogeneity.
Generation and biobanking of patient-derived glioblastoma organoids and their application in CAR T cell testing.
MUC1 stimulates EGFR expression and function in endometrial cancer.
Multilayered, Hyaluronic Acid-Based Hydrogel Formulations Suitable for Automated 3D High Throughput Drug Screening of Cancer-Stromal Cell Cocultures.
Cross-talk between EGFR and T-cadherin: EGFR activation promotes T-cadherin localization to intercellular contacts.
Efficacy and mechanism of action of Proellex, an antiprogestin in aromatase overexpressing and Letrozole resistant T47D breast cancer cells.
Triepitopic antibody fusions inhibit cetuximab-resistant BRAF and KRAS mutant tumors via EGFR signal repression.
Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines.
Coexpression of SGLT1 and EGFR is associated with tumor differentiation in oral squamous cell carcinoma.
Enrichment of circulating tumor cells from a large blood volume using leukapheresis and elutriation: proof of concept.
Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies.
(-)-Epigallocatechin-3-gallate down-regulates EGFR, MMP-2, MMP-9 and EMMPRIN and inhibits the invasion of MCF-7 tamoxifen-resistant cells.
Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action.
Evaluation of PTEN and Mcl-1 expressions in NSCLC expressing wild-type or mutated EGFR.
Determination of the minimal melatonin exposure required to induce osteoblast differentiation from human mesenchymal stem cells and these effects on downstream signaling pathways.
Concurrent inhibition of NF-kappaB, cyclooxygenase-2, and epidermal growth factor receptor leads to greater anti-tumor activity in pancreatic cancer.
Design of surfaces for liquid crystal-based bioanalytical assays.
Activity and cellular localization of an oncogenic glioblastoma multiforme-associated EGF receptor mutant possessing a duplicated kinase domain.
Overexpression of cortactin increases invasion potential in oral squamous cell carcinoma.
Proteomic and immunologic analyses of brain tumor exosomes.
Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer.
Erlotinib and bevacizumab have synergistic activity against melanoma.
Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR.
Sennoside B inhibits PDGF receptor signaling and cell proliferation induced by PDGF-BB in human osteosarcoma cells.
miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy.
Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells.
Overexpression of JKTBP1 induces androgen-independent LNCaP cell proliferation through activation of epidermal growth factor-receptor (EGF-R).
Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins.
Engineering of PDMS surfaces for use in microsystems for capture and isolation of complex and biomedically important proteins: epidermal growth factor receptor as a model system.
Activation of extracellular signal-regulated kinase by 12-hydroxyheptadecatrienoic acid in prostate cancer PC3 cells.
EGF-independent activation of cell-surface EGF receptors harboring mutations found in gefitinib-sensitive lung cancer.
Type II combi-molecules: design and binary targeting properties of the novel triazolinium-containing molecules JDD36 and JDE05.
Truncation of annexin A1 is a regulatory lever for linking epidermal growth factor signaling with cytosolic phospholipase A2 in normal and malignant squamous epithelial cells.
Structure-guided development of affinity probes for tyrosine kinases using chemical genetics.
Radiotherapy response in oral squamous carcinoma cell lines: evaluation of apoptotic proteins as prognostic factors.
Improved transduction of human corneal epithelial progenitor cells with cell-targeting adenoviral vectors.
A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma.
Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors.
Estrogen receptors in membrane lipid rafts and signal transduction in breast cancer.
Multiple acquired renal carcinoma tumor capabilities abolished upon silencing of ADAM17.
Herpes simplex virus 1 amplicon vector-mediated siRNA targeting epidermal growth factor receptor inhibits growth of human glioma cells in vivo.
Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells.
Inhibition of the type III epidermal growth factor receptor variant mutant receptor by dominant-negative EGFR-CD533 enhances malignant glioma cell radiosensitivity.
HER-2/neu overexpression increases the viable hypoxic cell population within solid tumors without causing changes in tumor vascularization.
In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase.
In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase.
AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Expression of a naturally occurring constitutively active variant of the epidermal growth factor receptor in mouse fibroblasts increases motility.
The combi-targeting concept: dissection of the binary mechanism of action of the combi-triazene SMA41 in vitro and antitumor activity in vivo.
Domain-level antibody epitope mapping through yeast surface display of epidermal growth factor receptor fragments.
Broadly distributed chemical reactivity of natural antibodies expressed in coordination with specific antigen binding activity.
Combinatorial efficacy achieved through two-point blockade within a signaling pathway-a chemical genetic approach.
Inhibition of epidermal growth factor receptor-mediated signaling by "Combi-triazene" BJ2000, a new probe for Combi-Targeting postulates.
Epidermal growth factor receptor mutation type III transfected into a small cell lung cancer cell line is predominantly localized at the cell surface and enhances the malignant phenotype.
Epidermal growth factor receptor mutation type III transfected into a small cell lung cancer cell line is predominantly localized at the cell surface and enhances the malignant phenotype.
Neuregulin expression, function, and signaling in human ovarian cancer cells.
Adenovirus-mediated overexpression of dominant negative epidermal growth factor receptor-CD533 as a gene therapeutic approach radiosensitizes human carcinoma and malignant glioma cells.
Adenovirus-mediated overexpression of dominant negative epidermal growth factor receptor-CD533 as a gene therapeutic approach radiosensitizes human carcinoma and malignant glioma cells.
Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells.
Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells.
Cell migration and MMP-9 secretion are increased by epidermal growth factor in HaCaT-ras transfected cells.
Cell migration and MMP-9 secretion are increased by epidermal growth factor in HaCaT-ras transfected cells.
Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas.
Jacob F, Salinas RD, Zhang DY, Nguyen PTT, Schnoll JG, Wong SZH, Thokala R, Sheikh S, Saxena D, Prokop S, Liu DA, Qian X, Petrov D, Lucas T, Chen HI, Dorsey JF, Christian KM, Binder ZA, Nasrallah M, Brem S, O'Rourke DM, Ming GL, Song H
Cell 2020 Jan 9;180(1):188-204.e22
Cell 2020 Jan 9;180(1):188-204.e22
Generation and biobanking of patient-derived glioblastoma organoids and their application in CAR T cell testing.
Jacob F, Ming GL, Song H
Nature protocols 2020 Dec;15(12):4000-4033
Nature protocols 2020 Dec;15(12):4000-4033
MUC1 stimulates EGFR expression and function in endometrial cancer.
Engel BJ, Bowser JL, Broaddus RR, Carson DD
Oncotarget 2016 May 31;7(22):32796-809
Oncotarget 2016 May 31;7(22):32796-809
Multilayered, Hyaluronic Acid-Based Hydrogel Formulations Suitable for Automated 3D High Throughput Drug Screening of Cancer-Stromal Cell Cocultures.
Engel BJ, Constantinou PE, Sablatura LK, Doty NJ, Carson DD, Farach-Carson MC, Harrington DA, Zarembinski TI
Advanced healthcare materials 2015 Aug 5;4(11):1664-74
Advanced healthcare materials 2015 Aug 5;4(11):1664-74
Cross-talk between EGFR and T-cadherin: EGFR activation promotes T-cadherin localization to intercellular contacts.
Kyriakakis E, Maslova K, Frachet A, Ferri N, Contini A, Pfaff D, Erne P, Resink TJ, Philippova M
Cellular signalling 2013 May;25(5):1044-53
Cellular signalling 2013 May;25(5):1044-53
Efficacy and mechanism of action of Proellex, an antiprogestin in aromatase overexpressing and Letrozole resistant T47D breast cancer cells.
Gupta A, Mehta R, Alimirah F, Peng X, Murillo G, Wiehle R, Mehta RG
The Journal of steroid biochemistry and molecular biology 2013 Jan;133:30-42
The Journal of steroid biochemistry and molecular biology 2013 Jan;133:30-42
Triepitopic antibody fusions inhibit cetuximab-resistant BRAF and KRAS mutant tumors via EGFR signal repression.
Spangler JB, Manzari MT, Rosalia EK, Chen TF, Wittrup KD
Journal of molecular biology 2012 Sep 28;422(4):532-44
Journal of molecular biology 2012 Sep 28;422(4):532-44
Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines.
Collins DM, O'Donovan N, McGowan PM, O'Sullivan F, Duffy MJ, Crown J
Annals of oncology : official journal of the European Society for Medical Oncology 2012 Jul;23(7):1788-95
Annals of oncology : official journal of the European Society for Medical Oncology 2012 Jul;23(7):1788-95
Coexpression of SGLT1 and EGFR is associated with tumor differentiation in oral squamous cell carcinoma.
Hanabata Y, Nakajima Y, Morita K, Kayamori K, Omura K
Odontology 2012 Jul;100(2):156-63
Odontology 2012 Jul;100(2):156-63
Enrichment of circulating tumor cells from a large blood volume using leukapheresis and elutriation: proof of concept.
Eifler RL, Lind J, Falkenhagen D, Weber V, Fischer MB, Zeillinger R
Cytometry. Part B, Clinical cytometry 2011 Mar;80(2):100-11
Cytometry. Part B, Clinical cytometry 2011 Mar;80(2):100-11
Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies.
Cho J, Pastorino S, Zeng Q, Xu X, Johnson W, Vandenberg S, Verhaak R, Cherniack AD, Watanabe H, Dutt A, Kwon J, Chao YS, Onofrio RC, Chiang D, Yuza Y, Kesari S, Meyerson M
Cancer research 2011 Dec 15;71(24):7587-96
Cancer research 2011 Dec 15;71(24):7587-96
(-)-Epigallocatechin-3-gallate down-regulates EGFR, MMP-2, MMP-9 and EMMPRIN and inhibits the invasion of MCF-7 tamoxifen-resistant cells.
Farabegoli F, Papi A, Orlandi M
Bioscience reports 2011 Apr;31(2):99-108
Bioscience reports 2011 Apr;31(2):99-108
Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action.
DeFazio-Eli L, Strommen K, Dao-Pick T, Parry G, Goodman L, Winslow J
Breast cancer research : BCR 2011 Apr 15;13(2):R44
Breast cancer research : BCR 2011 Apr 15;13(2):R44
Evaluation of PTEN and Mcl-1 expressions in NSCLC expressing wild-type or mutated EGFR.
Cetin Z, Ozbilim G, Erdogan A, Luleci G, Karauzum SB
Medical oncology (Northwood, London, England) 2010 Sep;27(3):853-60
Medical oncology (Northwood, London, England) 2010 Sep;27(3):853-60
Determination of the minimal melatonin exposure required to induce osteoblast differentiation from human mesenchymal stem cells and these effects on downstream signaling pathways.
Sethi S, Radio NM, Kotlarczyk MP, Chen CT, Wei YH, Jockers R, Witt-Enderby PA
Journal of pineal research 2010 Oct;49(3):222-38
Journal of pineal research 2010 Oct;49(3):222-38
Concurrent inhibition of NF-kappaB, cyclooxygenase-2, and epidermal growth factor receptor leads to greater anti-tumor activity in pancreatic cancer.
Ali S, Banerjee S, Schaffert JM, El-Rayes BF, Philip PA, Sarkar FH
Journal of cellular biochemistry 2010 May;110(1):171-81
Journal of cellular biochemistry 2010 May;110(1):171-81
Design of surfaces for liquid crystal-based bioanalytical assays.
Lowe AM, Ozer BH, Bai Y, Bertics PJ, Abbott NL
ACS applied materials & interfaces 2010 Mar;2(3):722-31
ACS applied materials & interfaces 2010 Mar;2(3):722-31
Activity and cellular localization of an oncogenic glioblastoma multiforme-associated EGF receptor mutant possessing a duplicated kinase domain.
Ozer BH, Wiepz GJ, Bertics PJ
Oncogene 2010 Feb 11;29(6):855-64
Oncogene 2010 Feb 11;29(6):855-64
Overexpression of cortactin increases invasion potential in oral squamous cell carcinoma.
Yamada S, Yanamoto S, Kawasaki G, Mizuno A, Nemoto TK
Pathology oncology research : POR 2010 Dec;16(4):523-31
Pathology oncology research : POR 2010 Dec;16(4):523-31
Proteomic and immunologic analyses of brain tumor exosomes.
Graner MW, Alzate O, Dechkovskaia AM, Keene JD, Sampson JH, Mitchell DA, Bigner DD
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2009 May;23(5):1541-57
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2009 May;23(5):1541-57
Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer.
Corkery B, Crown J, Clynes M, O'Donovan N
Annals of oncology : official journal of the European Society for Medical Oncology 2009 May;20(5):862-7
Annals of oncology : official journal of the European Society for Medical Oncology 2009 May;20(5):862-7
Erlotinib and bevacizumab have synergistic activity against melanoma.
Schicher N, Paulitschke V, Swoboda A, Kunstfeld R, Loewe R, Pilarski P, Pehamberger H, Hoeller C
Clinical cancer research : an official journal of the American Association for Cancer Research 2009 May 15;15(10):3495-502
Clinical cancer research : an official journal of the American Association for Cancer Research 2009 May 15;15(10):3495-502
Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR.
Al-Nedawi K, Meehan B, Kerbel RS, Allison AC, Rak J
Proceedings of the National Academy of Sciences of the United States of America 2009 Mar 10;106(10):3794-9
Proceedings of the National Academy of Sciences of the United States of America 2009 Mar 10;106(10):3794-9
Sennoside B inhibits PDGF receptor signaling and cell proliferation induced by PDGF-BB in human osteosarcoma cells.
Chen YC, Chang CN, Hsu HC, Chiou SJ, Lee LT, Hseu TH
Life sciences 2009 Jun 19;84(25-26):915-22
Life sciences 2009 Jun 19;84(25-26):915-22
miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy.
Adam L, Zhong M, Choi W, Qi W, Nicoloso M, Arora A, Calin G, Wang H, Siefker-Radtke A, McConkey D, Bar-Eli M, Dinney C
Clinical cancer research : an official journal of the American Association for Cancer Research 2009 Aug 15;15(16):5060-72
Clinical cancer research : an official journal of the American Association for Cancer Research 2009 Aug 15;15(16):5060-72
Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells.
Black PC, Brown GA, Inamoto T, Shrader M, Arora A, Siefker-Radtke AO, Adam L, Theodorescu D, Wu X, Munsell MF, Bar-Eli M, McConkey DJ, Dinney CP
Clinical cancer research : an official journal of the American Association for Cancer Research 2008 Mar 1;14(5):1478-86
Clinical cancer research : an official journal of the American Association for Cancer Research 2008 Mar 1;14(5):1478-86
Overexpression of JKTBP1 induces androgen-independent LNCaP cell proliferation through activation of epidermal growth factor-receptor (EGF-R).
Wu YY, Li H, Lv XY, Wei Q, Li X, Liu XY, Zhou Q, Wei YQ
Cell biochemistry and function 2008 Jun;26(4):467-77
Cell biochemistry and function 2008 Jun;26(4):467-77
Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins.
Guix M, Faber AC, Wang SE, Olivares MG, Song Y, Qu S, Rinehart C, Seidel B, Yee D, Arteaga CL, Engelman JA
The Journal of clinical investigation 2008 Jul;118(7):2609-19
The Journal of clinical investigation 2008 Jul;118(7):2609-19
Engineering of PDMS surfaces for use in microsystems for capture and isolation of complex and biomedically important proteins: epidermal growth factor receptor as a model system.
Lowe AM, Ozer BH, Wiepz GJ, Bertics PJ, Abbott NL
Lab on a chip 2008 Aug;8(8):1357-64
Lab on a chip 2008 Aug;8(8):1357-64
Activation of extracellular signal-regulated kinase by 12-hydroxyheptadecatrienoic acid in prostate cancer PC3 cells.
Li X, Wei J, Tai HH
Archives of biochemistry and biophysics 2007 Nov 1;467(1):20-30
Archives of biochemistry and biophysics 2007 Nov 1;467(1):20-30
EGF-independent activation of cell-surface EGF receptors harboring mutations found in gefitinib-sensitive lung cancer.
Choi SH, Mendrola JM, Lemmon MA
Oncogene 2007 Mar 8;26(11):1567-76
Oncogene 2007 Mar 8;26(11):1567-76
Type II combi-molecules: design and binary targeting properties of the novel triazolinium-containing molecules JDD36 and JDE05.
Qiu Q, Domarkas J, Banerjee R, Katsoulas A, McNamee JP, Jean-Claude BJ
Anti-cancer drugs 2007 Feb;18(2):171-7
Anti-cancer drugs 2007 Feb;18(2):171-7
Truncation of annexin A1 is a regulatory lever for linking epidermal growth factor signaling with cytosolic phospholipase A2 in normal and malignant squamous epithelial cells.
Sakaguchi M, Murata H, Sonegawa H, Sakaguchi Y, Futami J, Kitazoe M, Yamada H, Huh NH
The Journal of biological chemistry 2007 Dec 7;282(49):35679-86
The Journal of biological chemistry 2007 Dec 7;282(49):35679-86
Structure-guided development of affinity probes for tyrosine kinases using chemical genetics.
Blair JA, Rauh D, Kung C, Yun CH, Fan QW, Rode H, Zhang C, Eck MJ, Weiss WA, Shokat KM
Nature chemical biology 2007 Apr;3(4):229-38
Nature chemical biology 2007 Apr;3(4):229-38
Radiotherapy response in oral squamous carcinoma cell lines: evaluation of apoptotic proteins as prognostic factors.
Roberg K, Jonsson AC, Grénman R, Norberg-Spaak L
Head & neck 2007 Apr;29(4):325-34
Head & neck 2007 Apr;29(4):325-34
Improved transduction of human corneal epithelial progenitor cells with cell-targeting adenoviral vectors.
Chen Z, Mok H, Pflugfelder SC, Li DQ, Barry MA
Experimental eye research 2006 Oct;83(4):798-806
Experimental eye research 2006 Oct;83(4):798-806
A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma.
Fan QW, Knight ZA, Goldenberg DD, Yu W, Mostov KE, Stokoe D, Shokat KM, Weiss WA
Cancer cell 2006 May;9(5):341-9
Cancer cell 2006 May;9(5):341-9
Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors.
Damiano V, Caputo R, Bianco R, D'Armiento FP, Leonardi A, De Placido S, Bianco AR, Agrawal S, Ciardiello F, Tortora G
Clinical cancer research : an official journal of the American Association for Cancer Research 2006 Jan 15;12(2):577-83
Clinical cancer research : an official journal of the American Association for Cancer Research 2006 Jan 15;12(2):577-83
Estrogen receptors in membrane lipid rafts and signal transduction in breast cancer.
Márquez DC, Chen HW, Curran EM, Welshons WV, Pietras RJ
Molecular and cellular endocrinology 2006 Feb 26;246(1-2):91-100
Molecular and cellular endocrinology 2006 Feb 26;246(1-2):91-100
Multiple acquired renal carcinoma tumor capabilities abolished upon silencing of ADAM17.
Franovic A, Robert I, Smith K, Kurban G, Pause A, Gunaratnam L, Lee S
Cancer research 2006 Aug 15;66(16):8083-90
Cancer research 2006 Aug 15;66(16):8083-90
Herpes simplex virus 1 amplicon vector-mediated siRNA targeting epidermal growth factor receptor inhibits growth of human glioma cells in vivo.
Saydam O, Glauser DL, Heid I, Turkeri G, Hilbe M, Jacobs AH, Ackermann M, Fraefel C
Molecular therapy : the journal of the American Society of Gene Therapy 2005 Nov;12(5):803-12
Molecular therapy : the journal of the American Society of Gene Therapy 2005 Nov;12(5):803-12
Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells.
Kassouf W, Dinney CP, Brown G, McConkey DJ, Diehl AJ, Bar-Eli M, Adam L
Cancer research 2005 Nov 15;65(22):10524-35
Cancer research 2005 Nov 15;65(22):10524-35
Inhibition of the type III epidermal growth factor receptor variant mutant receptor by dominant-negative EGFR-CD533 enhances malignant glioma cell radiosensitivity.
Lammering G, Hewit TH, Holmes M, Valerie K, Hawkins W, Lin PS, Mikkelsen RB, Schmidt-Ullrich RK
Clinical cancer research : an official journal of the American Association for Cancer Research 2004 Oct 1;10(19):6732-43
Clinical cancer research : an official journal of the American Association for Cancer Research 2004 Oct 1;10(19):6732-43
HER-2/neu overexpression increases the viable hypoxic cell population within solid tumors without causing changes in tumor vascularization.
Dragowska WH, Warburton C, Yapp DT, Minchinton AI, Hu Y, Waterhouse DN, Gelmon K, Skov K, Woo J, Masin D, Huxham LA, Kyle AH, Bally MB
Molecular cancer research : MCR 2004 Nov;2(11):606-19
Molecular cancer research : MCR 2004 Nov;2(11):606-19
In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase.
García-Echeverría C, Pearson MA, Marti A, Meyer T, Mestan J, Zimmermann J, Gao J, Brueggen J, Capraro HG, Cozens R, Evans DB, Fabbro D, Furet P, Porta DG, Liebetanz J, Martiny-Baron G, Ruetz S, Hofmann F
Cancer cell 2004 Mar;5(3):231-9
Cancer cell 2004 Mar;5(3):231-9
In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase.
García-Echeverría C, Pearson MA, Marti A, Meyer T, Mestan J, Zimmermann J, Gao J, Brueggen J, Capraro HG, Cozens R, Evans DB, Fabbro D, Furet P, Porta DG, Liebetanz J, Martiny-Baron G, Ruetz S, Hofmann F
Cancer cell 2004 Mar;5(3):231-9
Cancer cell 2004 Mar;5(3):231-9
AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G
Cancer research 2004 Jul 15;64(14):4931-41
Cancer research 2004 Jul 15;64(14):4931-41
Expression of a naturally occurring constitutively active variant of the epidermal growth factor receptor in mouse fibroblasts increases motility.
Pedersen MW, Tkach V, Pedersen N, Berezin V, Poulsen HS
International journal of cancer 2004 Feb 20;108(5):643-53
International journal of cancer 2004 Feb 20;108(5):643-53
The combi-targeting concept: dissection of the binary mechanism of action of the combi-triazene SMA41 in vitro and antitumor activity in vivo.
Matheson SL, McNamee JP, Wang T, Alaoui-Jamali MA, Tari AM, Jean-Claude BJ
The Journal of pharmacology and experimental therapeutics 2004 Dec;311(3):1163-70
The Journal of pharmacology and experimental therapeutics 2004 Dec;311(3):1163-70
Domain-level antibody epitope mapping through yeast surface display of epidermal growth factor receptor fragments.
Cochran JR, Kim YS, Olsen MJ, Bhandari R, Wittrup KD
Journal of immunological methods 2004 Apr;287(1-2):147-58
Journal of immunological methods 2004 Apr;287(1-2):147-58
Broadly distributed chemical reactivity of natural antibodies expressed in coordination with specific antigen binding activity.
Planque S, Taguchi H, Burr G, Bhatia G, Karle S, Zhou YX, Nishiyama Y, Paul S
The Journal of biological chemistry 2003 May 30;278(22):20436-43
The Journal of biological chemistry 2003 May 30;278(22):20436-43
Combinatorial efficacy achieved through two-point blockade within a signaling pathway-a chemical genetic approach.
Fan QW, Specht KM, Zhang C, Goldenberg DD, Shokat KM, Weiss WA
Cancer research 2003 Dec 15;63(24):8930-8
Cancer research 2003 Dec 15;63(24):8930-8
Inhibition of epidermal growth factor receptor-mediated signaling by "Combi-triazene" BJ2000, a new probe for Combi-Targeting postulates.
Brahimi F, Matheson SL, Dudouit F, McNamee JP, Tari AM, Jean-Claude BJ
The Journal of pharmacology and experimental therapeutics 2002 Oct;303(1):238-46
The Journal of pharmacology and experimental therapeutics 2002 Oct;303(1):238-46
Epidermal growth factor receptor mutation type III transfected into a small cell lung cancer cell line is predominantly localized at the cell surface and enhances the malignant phenotype.
Damstrup L, Wandahl Pedersen M, Bastholm L, Elling F, Skovgaard Poulsen H
International journal of cancer 2002 Jan 1;97(1):7-14
International journal of cancer 2002 Jan 1;97(1):7-14
Epidermal growth factor receptor mutation type III transfected into a small cell lung cancer cell line is predominantly localized at the cell surface and enhances the malignant phenotype.
Damstrup L, Wandahl Pedersen M, Bastholm L, Elling F, Skovgaard Poulsen H
International journal of cancer 2002 Jan 1;97(1):7-14
International journal of cancer 2002 Jan 1;97(1):7-14
Neuregulin expression, function, and signaling in human ovarian cancer cells.
Gilmour LM, Macleod KG, McCaig A, Sewell JM, Gullick WJ, Smyth JF, Langdon SP
Clinical cancer research : an official journal of the American Association for Cancer Research 2002 Dec;8(12):3933-42
Clinical cancer research : an official journal of the American Association for Cancer Research 2002 Dec;8(12):3933-42
Adenovirus-mediated overexpression of dominant negative epidermal growth factor receptor-CD533 as a gene therapeutic approach radiosensitizes human carcinoma and malignant glioma cells.
Lammering G, Lin PS, Contessa JN, Hampton JL, Valerie K, Schmidt-Ullrich RK
International journal of radiation oncology, biology, physics 2001 Nov 1;51(3):775-84
International journal of radiation oncology, biology, physics 2001 Nov 1;51(3):775-84
Adenovirus-mediated overexpression of dominant negative epidermal growth factor receptor-CD533 as a gene therapeutic approach radiosensitizes human carcinoma and malignant glioma cells.
Lammering G, Lin PS, Contessa JN, Hampton JL, Valerie K, Schmidt-Ullrich RK
International journal of radiation oncology, biology, physics 2001 Nov 1;51(3):775-84
International journal of radiation oncology, biology, physics 2001 Nov 1;51(3):775-84
Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells.
Bandyopadhyay D, Mandal M, Adam L, Mendelsohn J, Kumar R
The Journal of biological chemistry 1998 Jan 16;273(3):1568-73
The Journal of biological chemistry 1998 Jan 16;273(3):1568-73
Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells.
Bandyopadhyay D, Mandal M, Adam L, Mendelsohn J, Kumar R
The Journal of biological chemistry 1998 Jan 16;273(3):1568-73
The Journal of biological chemistry 1998 Jan 16;273(3):1568-73
Cell migration and MMP-9 secretion are increased by epidermal growth factor in HaCaT-ras transfected cells.
Charvat S, Chignol MC, Souchier C, Le Griel C, Schmitt D, Serres M
Experimental dermatology 1998 Aug;7(4):184-90
Experimental dermatology 1998 Aug;7(4):184-90
Cell migration and MMP-9 secretion are increased by epidermal growth factor in HaCaT-ras transfected cells.
Charvat S, Chignol MC, Souchier C, Le Griel C, Schmitt D, Serres M
Experimental dermatology 1998 Aug;7(4):184-90
Experimental dermatology 1998 Aug;7(4):184-90
Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas.
Wikstrand CJ, Hale LP, Batra SK, Hill ML, Humphrey PA, Kurpad SN, McLendon RE, Moscatello D, Pegram CN, Reist CJ
Cancer research 1995 Jul 15;55(14):3140-8
Cancer research 1995 Jul 15;55(14):3140-8
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis was performed on whole cell extracts (30 µg lysate) of A431 (Lane 1), Mouse Skin (Lane 2) and Mouse Placenta (Lane 3). The blots were probed with Anti-EGFR Mouse Monoclonal Antibody (Product # MA1-12693, 0.5-1 µg/mL) and detected by chemiluminescence Goat anti-Mouse IgG (H+L) Secondary Antibody, HRP conjugate (Product # 62-6520, 1:4000 dilution). A 180 kDa band corresponding to EGFR was observed across cell lines tested and a 60 kDa band corresponding to EGFR in tissues tested. Known quantity of protein samples were electrophoresed using Novex® NuPAGE®10 % Bis-Tris gel (Product # NP0301BOX), XCell SureLock™ Electrophoresis System (Product # EI0002) and Novex® Sharp Pre-Stained Protein Standard (Product # LC5800). Resolved proteins were then transferred onto a nitrocellulose membrane by overnight wet transfer method. The membrane was probed with the relevant primary and secondary Antibody following blocking with 5 % skimmed milk. Chemiluminescent detection was performed using Pierce™ ECL Western Blotting Substrate (Product # 32106).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunofluorescence analysis of EGFR was performed using 90% confluent log phase A-431 cells. The cells were fixed with 4% paraformaldehyde for 10 minutes, permeabilized with 0.1% Triton™ X-100 for 10 minutes, and blocked with 1% BSA for 1 hour at room temperature. The cells were labeled with EGFR Mouse monoclonal antibody (Product # MA1-12693) at 5 µg/mL in 0.1% BSA and incubated for 3 hours at room temperature and then labeled with Goat anti-Mouse IgG (H+L) Superclonal™ Secondary Antibody, Alexa Fluor® 488 conjugate (Product # A28175) at a dilution of 1:2000 for 45 minutes at room temperature (Panel a: green). Nuclei (Panel b: blue) were stained with SlowFade® Gold Antifade Mountant with DAPI (Product # S36938). F-actin (Panel c: red) was stained with Rhodamine Phalloidin (Product # R415, 1:300). Panel d represents the merged image showing membrane localization. Panel e shows the no primary antibody control. The images were captured at 60X magnification.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunofluorescence analysis of EGFR was done on 90% confluent log phase A431 cells. The cells were fixed with 4% paraformaldehyde for 10 minutes, permeabilized with 0.1% Triton™ X-100 for 10 minutes, and blocked with 1% BSA for 1 hour at room temperature. The cells were labeled EGFR (H11) Mouse Monoclonal Antibody (Product # MA1-12693) at 2 µg/mL in 0.1% BSA and incubated for 3 hours at room temperature and then labeled with Goat anti-Mouse IgG (H+L) Superclonal™ Secondary Antibody, Alexa Fluor® 488 conjugate (Product # A28175) at a dilution of 1:2000 for 45 minutes at room temperature (Panel a: green). Nuclei (Panel b: blue) were stained with SlowFade® Gold Antifade Mountant with DAPI (Product # S36938). F-actin (Panel c: red) was stained with Alexa Fluor® 555 Rhodamine Phalloidin (Product # R415, 1:300). Panel d is a merged image showing membranous localization. Panel e is a no primary antibody control. The images were captured at 60X magnification.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunofluorescence analysis of EGFR was done on 70% confluent log phase A431 cells. The cells were fixed with 4% paraformaldehyde for 15 minutes, permeabilized with 0.1% Triton™ X-100 for 10 minutes, and blocked with 1% BSA for 1 hour at room temperature. The cells were subsequently labeled with EGFR Mouse Monoclonal Antibody (Product # MA1-12693) at 2 µg/mL in 0.1% BSA and incubated for 3 hours at room temperature and then labeled with Goat anti-Mouse IgG (H+L) Superclonal™ Secondary Antibody, Alexa Fluor® 488 conjugate (Product # A28175) at a dilution of 1:2000 for 45 minutes at room temperature. Nuclei (Blue) were stained with SlowFade® Gold Antifade Mountant DAPI (Product # S36938). F-actin (Red) was stained with Rhodamine Phalloidin (Product # R415, 1:300). EGFR signal was observed in control cell line (panels a-d) and not in the EGFR knockout (KO) cell line (panels f-i). Panels e and j represent the respective no primary controls. The images were captured at 60X magnification.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemical analysis of EGFR using a monoclonal antibody (Product # MA1-12693).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Flow cytometry analysis of EGFR was done on A-431 cells. Cells were fixed with 70% ethanol for 10 minutes, permeabilized with 0.25% Triton™ X-100 for 20 minutes, and blocked with 5% BSA for 30 minutes at room temperature. Cells were labeled with EGFR Mouse Monoclonal Antibody (MA112693, red histogram) or with mouse isotype control (yellow histogram) at 3-5 ug/million cells in 2.5% BSA. After incubation at room temperature for 2 hours, the cells were labeled with Alexa Fluor® 488 Rabbit Anti-Mouse Secondary Antibody (A11059) at a dilution of 1:400 for 30 minutes at room temperature. The representative 10,000 cells were acquired and analyzed for each sample using an Attune® Acoustic Focusing Cytometer. The purple histogram represents unstained control cells and the green histogram represents no-primary-antibody control.